

UBC.P-020  
PATENT APPLICATION

Please add claims 29-34 as follows:

29. (new) The method of claim 9, further comprising the step of administering to the individual a chemotherapy agent.

30. (new) The method of claim 9, further comprising the step of administering to the individual a second antisense oligodeoxynucleotide which inhibits expression of an anti-apoptotic protein other than TRPM-2.

31. (new) The method of claim 10, further comprising the step of administering to the individual a chemotherapy agent.

32. (new) The method of claim 10, further comprising the step of administering to the individual a second antisense oligodeoxynucleotide which inhibits expression of an anti-apoptotic protein other than TRPM-2.

33. (new) The method of claim 11, further comprising the step of administering to the individual a chemotherapy agent.

34. (new) The method of claim 11, further comprising the step of administering to the individual a second antisense oligodeoxynucleotide which inhibits expression of an anti-apoptotic protein other than TRPM-2.

REMARKS


The specification has been amended to provide a reference to the PCT application of which this is a national phase application. In addition, the claims have been amended to eliminate multiple dependency. No new matter has been added, and no new issues are raised. Thus, the Application is entitled to the reduced filing fee and expedited consideration inasmuch

UBC.P-020  
PATENT APPLICATION

as the IPER prepared in the IPEA/US indicated that all the requirements of PCT Article 33 (1)-(4) were met.

Applicants enclose a copy of the Abstract from the PCT application. In the event that the original abstract was removed from the application for printing, please insert this abstract in the application to conform with US rules requiring a copy of the abstract on a separate sheet.

Respectfully submitted,



Marina T. Larson, Ph.D.

Attorney for Applicant

+1 970 468 6600 x 152

UBC.P-020  
PATENT APPLICATION

MARKED UP COPY OF AMENDED CLAIMS

12. (amended) The method of [any of claims 8-11] claim 8, further comprising the step of administering to the individual a chemotherapy agent.

14. (amended) The method of [any of claims 8-11] claim 8, further comprising the step of administering to the individual a second antisense oligodeoxynucleotide which inhibits expression of an anti-apoptotic protein other than TRPM-2.